Clinical Trials Browser

INDUSTRY × Hematologic Neoplasms × navitoclax × Clear all

NCT00788684 2025-02-20

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Phase 1 Completed

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms